Simeguru peptide oral weight loss drug has already issued over 600,000 prescriptions, how much more market space is there?

With more and more GLP-1 class weight loss drugs entering the market, competition has become more intense. However, according to Novo Nordisk CEO Lars Fruergaard Jrgensen, the weight loss drug market is huge, and the pharmaceutical industry has only scratched the surface. Before the upcoming annual meeting of the Obesity Medicine Association next week, Jrgensen said in an interview with the media that the weight loss drugs currently offered by companies including Novo Nordisk, Eli Lilly, and various manufacturers of combination formulations in the United States can only meet the needs of 10% to 15% of obese patients. This statement comes as Novo Nordisk's rival Eli Lilly expands its competition into the field of oral formulations. Concerned about declining market share of Novo Nordisk's semaglutide weight loss drug, the company's stock price has fallen by nearly 30% this year, with a current market value of less than $130 billion. In January of this year, Novo Nordisk's oral semaglutide weight loss drug was the first to be introduced to the U.S. market. According to the latest data disclosed to First Finance by the company, the prescription volume of this oral weight loss drug has exceeded 600,000. UBS estimates that Eli Lilly's oral weight loss drugs and Novo Nordisk's oral semaglutide will generate a total of approximately $5 billion in revenue by 2026.